Phase 3 N=60 Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter
Coronary Artery Disease
Primary: Device Procedural Success — 98.3 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=114 Coping Skills Training for Adolescents With Fibromyalgia
Fibromyalgia
Primary: Change in FDI (Functional Disability Inventory) Scores at End of Study — 21.4; 19.2; 13.4; 17.0 units on a 0-60 scale — p=0.007
Phase 3 N=1,500 Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age
Meningococcal Disease
Primary: Percentage of Subjects With hSBA Seroresponse Against Serogroups A, C, W and Y One Month After Vaccination With MenACWY-CRM or MenACWY-PS — 93; 55; 82; 52 Percentage of…
N/A N=123 Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients
Hypertension · High Blood Pressure · Ventricular Hypertrophy
Primary: Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life — -3.3; -4.9 mm Hg
Phase 4 N=434 Comparative Infection Rates for the Codman BACTISEAL TM External Ventricular Drainage (EVD) System
Intraventricular Hemorrhage · Subarachnoid Hemorrhage
Primary: Number of Infections — 4; 5; 4; 5 Infections
N/A N=72 Breast Displacement and CT Radiation Dose
Computed Tomography · Radiation Dosage
Primary: Skin Entrance Radiation Dose During Computed Tomography (CT) — 1775; 1325; 625; 259 mrad
N/A N=50 Correlation of Auscultatory Severity of Aortic Stenosis With Trans Thoracic Echocardiography
Aortic Stenosis
Primary: Aortic Stenosis Acceleration Index Compared to Aortic Stenosis Severity — 21; 8; 1; 6 participants
Phase 3 N=1,708 Trial to Assess Chelation Therapy (TACT)
Coronary Artery Disease
Primary: A Composite of Total Mortality, Recurrent Myocardial Infarction, Stroke, Coronary Revascularization, and Hospitalization for Angina. — 108; 114; 122; 139 participants
Phase 1 N=20 A Study of Prasugrel in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics: Maximum Concentration (Cmax) of Prasugrel Test and Reference Formulation — 28.6; 28.1 nanograms per milliliter (ng/mL)
Phase 3 N=44 PTH & Ibandronate Combination Study (PICS)
Osteoporosis
Primary: P1NP (ng/ml) Change From Baseline. — 42; 186 Percent change from baseline
Phase 2 N=14 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
Neuromyelitis Optica · Devic's Disease
Primary: Median Number of Neuromyelitis Optica (NMO) Attacks Per Year — 3; 0 attacks per year — p=<0.0001
Phase 3 N=1,021 Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
Nausea
Primary: Home Record: Severity of Delayed Nausea — 1.88; 1.65; 1.87; 1.68 units on a scale — p=0.718
Phase 4 N=200 Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.
Influenza
Primary: Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Fluzone® or Fluzone® Intradermal or Fluzone® High-Dose…
Phase 3 N=807 Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
Depressive Disorder, Major
Primary: Percentage of Responders With a 50% or Greater Decrease From Baseline on the Hamilton Rating Scale for Depression, 17-item (HAM-D17) — 63; 67; 63; 66 percentage of…
Phase 4 N=83 Enamel Remineralization Potential of Dentifrices in Situ
Dental Caries
Primary: Percentage Surface Microhardness Recovery (%SMHR) of Enamel Specimens Exposed to NaF Toothpaste (1450ppmF) and SnF/NaF Toothpaste (1450ppmF) — 40.94; 17.88 Percentage of…